|
1
|
McGuire S: World Cancer Report 2014.
Geneva, Switzerland: World health organization, international
agency for research on cancer, WHO Press, 2015. Adv Nutr.
7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Takahashi S, Moriya T, Ishida T, Shibata
H, Sasano H, Ohuchi N and Ishioka C: Prediction of breast cancer
prognosis by gene expression profile of TP53 status. Cancer Sci.
99:324–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Atsushi T, Nagireddy P, Prachi M, Mathé
EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, et
al: MYC-driven accumulation of 2-hydroxyglutarate is associated
with breast cancer prognosis. J Clin Invest. 124:398–412. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Holmes MD, Chen WY, Schnitt SJ, Collins L,
Colditz GA, Hankinson SE and Tamimi RM: COX-2 expression predicts
worse breast cancer prognosis and does not modify the association
with aspirin. Breast Cancer Res Treat. 130:657–662. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kontzoglou K, Palla V, Karaolanis G,
Karaiskos I, Alexiou I, Pateras I, Konstantoudakis K and Stamatakos
M: Correlation between Ki67 and Breast Cancer Prognosis. Oncology.
84:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Decock J, Long JR, Laxton RC, Shu XO,
Hodgkinson C, Hendrickx W, Pearce EG, Gao YT, Pereira AC, Paridaens
R, et al: Association of matrix metalloproteinase-8 gene variation
with breast cancer prognosis. Cancer Res. 67:10214–10221. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Manjili MH, Najarian K and Wang XY:
Signatures of tumor-immune interactions as biomarkers for breast
cancer prognosis. Future Oncol. 8:703–711. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Z, Ni C, Chen W, Wu P, Wang Z, Yin
J, Huang J and Qiu F: Expression of CXCR4 and breast cancer
prognosis: A systematic review and meta-analysis. Bmc Cancer.
14:492014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang L, Song X, Wang X, Xie Y, Wang Z, Xu
Y, You X, Liang Z and Cao H: Circulating DNA of HOTAIR in serum is
a novel biomarker for breast cancer. Breast Cancer Res Treat.
152:199–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee YH, Liu X, Qiu F, O'Connor TR, Yen Y
and Ann DK: Correction: HP1β is a biomarker for breast cancer
prognosis and PARP inhibitor therapy. PLoS One. 10:e01248532015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garczyk S, von Stillfried S, Antonopoulos
W, Hartmann A, Schrauder MG, Fasching PA, Anzeneder T, Tannapfel A,
Ergönenc Y, Knüchel R, et al: Agr3 in breast cancer: Prognostic
impact and suitable serum-based biomarker for early cancer
detection. PLoS One. 10:e01221062015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brennan DJ, Kelly C, Rexhepaj E, Dervan
PA, Duffy MJ and Gallagher WM: Contribution of DNA and tissue
microarray technology to the identification and validation of
biomarkers and personalised medicine in breast cancer. Cancer
Genomics Proteomics. 4:121–134. 2007.PubMed/NCBI
|
|
13
|
Miecznikowski JC, Wang D, Liu S, Sucheston
L and Gold D: Comparative survival analysis of breast cancer
microarray studies identifies important prognostic genetic
pathways. BMC Cancer. 10:5732010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM,
Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu
J, et al: Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer. Lancet. 365:671–679.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hatzis C, Pusztai L, Valero V, Booser DJ,
Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, et
al: A genomic predictor of response and survival following
taxane-anthracycline chemotherapy for invasive breast cancer. JAMA.
305:1873–1881. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation,
visualization and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Langfelder P and Horvath S: WGCNA: An R
package for weighted correlation network analysis. BMC
Bioinformatics. 9:5592008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Becker RA, Chambers JM and Wilks AR: The
New S Language. Wadsworth & Brooks/Cole; Monterey: 1988,
View Article : Google Scholar
|
|
20
|
Nasmyth K: Viewpoint: Putting the cell
cycle in order. Science. 274:1643–1645. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shubbar E, Kovács A, Hajizadeh S, Parris
TZ, Nemes S, Gunnarsdóttir K, Einbeigi Z, Karlsson P and Helou K:
Elevated cyclin B2 expression in invasive breast carcinoma is
associated with unfavorable clinical outcome. Bmc Cancer. 13:12013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chou CP, Huang NC, Jhuang SJ, Pan HB, Peng
NJ, Cheng JT, Chen CF, Chen JJ and Chang TH: Ubiquitin-conjugating
enzyme UBE2C is highly expressed in breast microcalcification
lesions. PLoS One. 9:e939342014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Psyrri A, Kalogeras KT, Kronenwett R,
Wirtz RM, Batistatou A, Bournakis E, Timotheadou E, Gogas H,
Aravantinos G, Christodoulou C, et al: Prognostic significance of
UBE2C mRNA expression in high-risk early breast cancer. A Hellenic
Cooperative Oncology Group (HeCOG) Study. Ann Oncol. 23:1422–1427.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Psyrri D, Kronenwett R, Timotheadou E,
Wirtz RM, Onyenadum A, Pentheroudakis GE, Papadimitriou CA, Razis
E, Economopoulos T and Fountzilas G: Evaluation of the prognostic
value of UBE2C mRNA levels in early breast cancer. J Clinical
Oncol. 28 (15 suppl):S105702010. View Article : Google Scholar
|
|
25
|
Loussouarn D, Campion L, Leclair F,
Campone M, Charbonnel C, Ricolleau G, Gouraud W, Bataille R and
Jézéquel P: Validation of UBE2C protein as a prognostic marker in
node-positive breast cancer. Br J Cancer. 101:166–173. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han Q, Zhou C, Liu F, Xu G, Zheng R and
Zhang X: MicroRNA-196a post-transcriptionally upregulates the UBE2C
proto-oncogene and promotes cell proliferation in breast cancer.
Oncol Rep. 34:877–883. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rawat A, Gopal G, Selvaluxmy G and
Rajkumar T: Inhibition of ubiquitin conjugating enzyme UBE2C
reduces proliferation and sensitizes breast cancer cells to
radiation, doxorubicin, tamoxifen and letrozole. Cell Oncol
(Dordr). 36:459–467. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin SY, Pan HW, Liu SH, Jeng YM, Hu FC,
Peng SY, Lai PL and Hsu HC: ASPM is a novel marker for vascular
invasion, early recurrence, and poor prognosis of hepatocellular
carcinoma. Clin Cancer Res. 14:4814–4820. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brüning-Richardson A, Bond J, Alsiary R,
Richardson J, Cairns DA, McCormack L, Hutson R, Burns P, Wilkinson
N, Hall GD, et al: ASPM and microcephalin expression in epithelial
ovarian cancer correlates with tumour grade and survival. Br J
Cancer. 104:1602–1610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Francis RE, Myatt SS, Krol J, Hartman J,
Peck B, McGovern UB, Wang J, Guest SK, Filipovic A, Gojis O, et al:
FoxM1 is a downstream target and marker of HER2 overexpression in
breast cancer. Int J Oncol. 35:57–68. 2009.PubMed/NCBI
|
|
31
|
Ahmad A, Wang Z, Kong D, Ali S, Li Y,
Banerjee S, Ali R and Sarkar FH: Foxm1 down-regulation leads to
inhibition of proliferation, migration and invasion of breast
cancer cells through the modulation of extra-cellular matrix
degrading factors. Breast Cancer Res Treat. 122:337–346. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang C, Chen H, Tan G, Gao W, Cheng L,
Jiang X, Yu L and Tan Y: FOXM1 promotes the epithelial to
mesenchymal transition by stimulating the transcription of slug in
human breast cancer. Cancer Lett. 340:104–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kwok JM, Peck B, Monteiro LJ, Schwenen HD,
Millour J, Coombes RC, Myatt SS and Lam EW: FOXM1 confers acquired
cisplatin resistance in breast cancer cells. Mol Cancer Res.
8:24–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Millour J, Constantinidou D, Stavropoulou
AV, Wilson MS, Myatt SS, Kwok JM, Sivanandan K, Coombes RC, Medema
RH, Hartman J, et al: FOXM1 is a transcriptional target of ERalpha
and has a critical role in breast cancer endocrine sensitivity and
resistance. Oncogene. 29:2983–2995. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang H, Lu C, Li Q, Xie J, Chen T, Tan Y,
Wu C and Jiang J: The Role of Kif4A in doxorubicin-induced
apoptosis in breast cancer cells. Mol Cells. 37:812–818. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Colak D, Nofal A, Albakheet A, Nirmal M,
Jeprel H, Eldali A, Al-Tweigeri T, Tulbah A, Ajarim D, Malik OA, et
al: Age-specific gene expression signatures for breast tumors and
cross-species conserved potential cancer progression markers in
young women. PLoS One. 8:e632042013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kotian S, Banerjee T, Lockhart A, Huang K,
Catalyurek UV and Parvin JD: NUSAP1 influences the DNA damage
response by controlling BRCA1 protein levels. Cancer Biol Ther.
15:533–543. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ghayad SE, Vendrell JA, Bieche I, Spyratos
F, Dumontet C, Treilleux I, Lidereau R and Cohen PA: Identification
of TACC1, NOV, and PTTG1 as new candidate genes associated with
endocrine therapy resistance in breast cancer. J Mol Endocrinol.
42:87–103. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yoon CH, Kim MJ, Lee H, Kim RK, Lim EJ,
Yoo KC, Lee GH, Cui YH, Oh YS, Gye MC, et al: PTTG1 promotes tumor
malignancy via epithelial to mesenchymal transition and expansion
of cancer stem cell population. J Biol Chem. 287:19516–19527. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jeffery J, Sinha D, Srihari S, Kalimutho M
and Khanna KK: Beyond cytokinesis: The emerging roles of CEP55 in
tumorigenesis. Oncogene. 35:683–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Subramanian R, Wilson-Kubalek EM, Arthur
CP, Bick MJ, Campbell EA, Darst SA, Milligan RA and Kapoor TM:
Insights into antiparallel microtubule crosslinking by PRC1, a
conserved nonmotor microtubule binding protein. Cell. 142:433–443.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shrestha S, Wilmeth LJ, Eyer J and Shuster
CB: PRC1 controls spindle polarization and recruitment of
cytokinetic factors during monopolar cytokinesis. Mol Biol Cell.
23:1196–1207. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
van den Boom V, Rozenveld-Geugien M,
Bonardi F, Malanga D, van Gosliga D, Heijink AM, Viglietto G,
Morrone G, Fusetti F, Vellenga E and Schuringa JJ: Nonredundant and
locus-specific gene repression functions of PRC1 paralog family
members in human hematopoietic stem/progenitor cells. Blood.
121:2452–2461. 2013. View Article : Google Scholar : PubMed/NCBI
|
